Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) ('Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to ...

Calidi Biotherapeutics, Inc., a clinical-stage biotech company, announced it has entered a definitive agreement to immediately exercise existing warrants to purchase up to 6,595,000 shares of its ...

Calidi Biotherapeutics announced a public offering of 5 million shares at $0.85 each, aiming for $4.25 million in proceeds. Quiver AI Summary Calidi Biotherapeutics, Inc. announced the pricing of ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development a new generation of targeted immunotherapies.